Ignite Creation Date:
2025-12-26 @ 3:58 PM
Ignite Modification Date:
2026-03-02 @ 4:00 PM
Study NCT ID:
NCT01840306
Status:
COMPLETED
Last Update Posted:
2025-07-08
First Post:
2013-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 330}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-10-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2023-05-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-04', 'studyFirstSubmitDate': '2013-04-23', 'studyFirstSubmitQcDate': '2013-04-23', 'lastUpdatePostDateStruct': {'date': '2025-07-08', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-04-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2023-05-24', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Identification of Extra Cellular RNAs/proteins in sera from cancer patients', 'timeFrame': '7 years', 'description': 'Identification of EC RNAs/proteins in sera from cancer patients, which correlate with their response to treatment'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Breast Cancer', 'HER2 Positive Breast Cancer', 'HER2 Negative Breast Cancer']}, 'descriptionModule': {'briefSummary': "Primary Objective:\n\n(i) To identify panels of RNAs and proteins predictive of response to HER2 targeted agents, considering clinical responses. (ii) To investigate associations between presence vs. absence (or relative levels) of identified extracellular (EC) RNAs/proteins and patients' clinicopathological characteristics, including age at diagnosis, time to progression and overall survival, as well as correlations with serum protein biomarkers routinely analysed for these patients. (iii) To compare HER2 positive samples versus HER2 negative samples for the existence of RNAs/proteins identified in (i) and (ii).\n\nSecondary Objective:\n\nTo develop a predictive model for use in the HER2 positive population based on the most accurate and sensitive combination of the identified biomarkers.", 'detailedDescription': 'This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study.\n\nCohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly diagnosed HER2 negative breast cancer patients.\n\nBlood specimens will be taken:\n\n* before starting treatment (cohort 1 and 2)\n* after receiving chemotherapy and before starting HER2 targeted treatment (if applicable) (cohort 1)\n* within one month following 1st treatment of HER2 targeted treatment (cohort 1)\n* approximately every 3 months (coinciding with formal disease assessment) while on HER2 targeted treatment for a maximum of 5 years (cohort 1)\n\nBlood will be processed to serum, which will be analysed for RNA and protein biomarkers.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': '* HER2 positive breast cancer:Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.\n* HER2 negative breast cancer:Female patients with newly diagnosed HER2 negative breast cancer.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patient with a newly diagnosed (including metastatic) HER2 positive breast cancer, who is to commence HER2 targeted treatment.\n\n OR\n\n \\- Patient with a newly diagnosed HER2 negative breast cancer, who is to commence any type of treatment.\n2. Patient must be female and aged 18 years or over.\n3. Patient must provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Patients who do not fulfil the inclusion criteria mentioned above'}, 'identificationModule': {'nctId': 'NCT01840306', 'briefTitle': 'Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer', 'organization': {'class': 'NETWORK', 'fullName': 'Cancer Trials Ireland'}, 'officialTitle': 'Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer', 'orgStudyIdInfo': {'id': 'ICORG 10-15'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1: HER2 positive breast cancer', 'description': 'Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.', 'interventionNames': ['Other: Biomarker Analysis']}, {'label': 'Cohort 2: HER2 negative breast cancer', 'description': 'Female patients with newly diagnosed HER2 negative breast cancer', 'interventionNames': ['Other: Biomarker Analysis']}], 'interventions': [{'name': 'Biomarker Analysis', 'type': 'OTHER', 'armGroupLabels': ['Cohort 1: HER2 positive breast cancer', 'Cohort 2: HER2 negative breast cancer']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Cork', 'country': 'Ireland', 'facility': 'Bon Secours Hospital', 'geoPoint': {'lat': 51.89797, 'lon': -8.47061}}, {'city': 'Cork', 'country': 'Ireland', 'facility': 'Cork University Hospital', 'geoPoint': {'lat': 51.89797, 'lon': -8.47061}}, {'city': 'Donegal', 'country': 'Ireland', 'facility': 'Letterkenny General Hospital', 'geoPoint': {'lat': 54.65378, 'lon': -8.11134}}, {'city': 'Drogheda', 'country': 'Ireland', 'facility': 'Our Lady of Lourdes Hospital', 'geoPoint': {'lat': 53.71889, 'lon': -6.34778}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': 'Beacon Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': 'Beaumont Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': "St James's Hospital", 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': "St Vincent's University Hospital", 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': "The Adelaide & Meath Hospital, Dublin Incorporating the National Children's Hospital", 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Sligo', 'country': 'Ireland', 'facility': 'Sligo General Hospital', 'geoPoint': {'lat': 54.26969, 'lon': -8.46943}}, {'city': 'Waterford', 'country': 'Ireland', 'facility': 'University Hospital Waterford', 'geoPoint': {'lat': 52.25833, 'lon': -7.11194}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cancer Trials Ireland', 'class': 'NETWORK'}, 'responsibleParty': {'type': 'SPONSOR'}}}}